三湘都市报2月12日讯 2月12日，湖南省医保局发布《关于印发湖南省城乡居民高血压糖尿病门诊用药 范围及医保支付标准（2026版）的通知》（以下简称《通知》），保障湖南城乡居民高血压、糖尿病 （以下简称"两病"）门诊用药待遇水平，建立科学规范的用药范围和支付标准动态调整机制。 "两病"用药范围"全纳入" 《通知》明确，以《关于印发湖南省城乡居民高血压糖尿病门诊用药范围及医保支付标准（2025年版） 的通知》规定的两病门诊用药范围及支付标准为基础，根据《国家基本医疗保险、工伤保险和生育保险 药品目录（2025年）》，对西药部分、协议期内谈判药品部分两个部分中高血压用药（药品分类代码 XC02抗高血压药、XC03利尿剂、XC07/XC07Aβ-受体阻滞剂、XC08钙通道阻滞剂、XC09作用于肾素- 血管紧张素系统的药物）、糖尿病用药（药品分类代码XA10），全部纳入两病用药范围。 《湖南省城乡居民高血压糖尿病门诊用药范围及医保支付标准（2026版）》从2026年2月14日起全省执 行，湖南省医保局将统一进行信息系统维护工作，各地不得以任何形式调整用药范围和支付标准。 "两病"叠加年度可报销960元 记者了解到，近 ...

Summary of Conference Call Notes Industry Overview - The conference call discusses the upcoming **11th National Drug Centralized Procurement (国采)**, expected to start in **July or August 2025**. The 10th round had extreme results due to a long time span and rule adjustments, leading to potential product registration backlog issues in the 11th round, with intensified competition and possible rule changes to avoid excessive low pricing [1][4][2]. Key Points and Arguments - **11th Batch Procurement Timing**: The 11th batch is likely to be delayed until the second half of the year due to the need for medical institutions to prepare reporting volumes, with only one round expected this year [2]. - **Biological Drug Procurement**: The biological drug procurement led by Anhui is set for execution by the end of **2025**, based on insulin procurement rules, focusing on moderate price reductions and a larger number of selected products [1][5][6]. - **Quality Control Measures**: The National Medical Products Administration (药监局) is responsible for quality control of selected products, while the National Healthcare Security Administration (医保局) has introduced new rules requiring companies to have market volume before gaining market share, ensuring fair competition [7][3]. - **Impact of New Rules on Original Drug Companies**: The new procurement rules favor original drug companies by allowing them to retain some market share even if not selected, and providing hospitals with more autonomy in choosing products [12][3]. - **Price Discrimination Issues**: The centralized procurement has provided a price benchmark, but there have been instances of price discrimination across provinces, leading to a downward spiral in drug prices and potential shortages [18][19]. - **Market Dynamics for Generic Drugs**: The procurement process has increased the penetration of competitive products in grassroots hospitals, while high-priced drugs have significant market expansion potential [11][21]. Additional Important Content - **Alliance Procurement Framework**: The shift to an alliance procurement framework has led to varied approaches among provinces, with some like Hebei being aggressive in pricing, while others like Guangdong and Xinjiang adopt a more balanced approach [8][9]. - **Future Alliance Plans**: Major alliances for procurement include those led by Sichuan, Xinjiang, Guangdong, and Tianjin, with Shanghai and Jiangsu considering joining new projects [9]. - **Impact on Marketing Strategies**: Original drug companies are adjusting their marketing strategies, increasing collaboration with e-commerce channels to enhance drug accessibility and sales [22][24]. - **Medicare Payment Standards**: The establishment of Medicare payment standards is expected to significantly impact drug prices and market dynamics, potentially leading to a unified pricing structure across different regions [13][20]. - **Challenges for Innovative Drugs**: The procurement policies may limit the development of innovative drugs due to low pricing, which could discourage research and development efforts in the pharmaceutical industry [25][26]. This summary encapsulates the critical insights and implications from the conference call regarding the upcoming drug procurement policies and their potential impact on the pharmaceutical industry.